Serum levels of the osteoprotegerin, receptor activator of nuclear factor κ-B ligand, metal loproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute myocardial infarction

被引:19
作者
Halapas, Antonios [1 ,2 ]
Zacharoulis, Achilleas [2 ]
Theocharis, Stamatios [3 ]
Karavidas, Apostolos [2 ]
Korres, Dirnitrios [2 ]
Papadopoulos, Kostantinos [2 ]
Katopodis, Harris [1 ]
Stavropoulou, Anastasia [1 ]
Lembessis, Peter [1 ]
Xiromeritis, Costas [1 ]
Zacharoulis, Apostolos [2 ]
Koutsilieris, Michael [1 ]
机构
[1] Univ Athens, Sch Med, Dept Expt Physiol, GR-11527 Athens, Greece
[2] Gen Hosp G Genimmatas, Dept Cardiol, Athens, Greece
[3] Univ Athens, Sch Med, Dept Forens Med & Toxicol, GR-11527 Athens, Greece
关键词
extracellular matrix; matrix metalloproteinases; myocardial infarction; osteoprotegerin; receptor activator of nuclear factor kappa-B ligand; tissue inhibitors of metalloproteinase;
D O I
10.1515/CCLM.2008.091
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL) are critical regulators of bone remodeling and RANKL/RANK signaling could also play an important role in the remodeling process of several tissues, such as myocardium. Therefore, we investigated whether the serum concentrations of OPG and RANKL correlate with the serum levels of metalloproteinase-1 (MMP-1), MMP-9 and tissue inhibitors of MMP-1 (TIMP-1)), which are known regulators of myocardial healing in acute myocardial infarction (AMI) patients. Methods: We analyzed blood samples from 51 consecutively hospitalized men with AMI, 12 men with established ischemic heart failure (New York Heart Association category II, NYHA-II) and 12 healthy men age-matched to the NYHA-II patients. Serum levels of MMP-1, MMP-9, TIMP-1, OPG and RANKL were quantified using commercially available ELISA kits. AMI patients were sampled 4 days and 6 months after MI. Results: Our data revealed increased serum levels of OPG, RANKL, MMP-1 and TIMP-1 levels and significant correlations between increased RANKL levels and MMP-1 and TIMP-1 serum levels 6 months after MI. In addition, the ratio OPG/RANKL was very low 6 months after MI, suggesting that the nuclear factor kappa-B signaling is possibly more active 6 months post-MI than it is on day 4 post-MI. Conclusions: Our data suggest that OPG, RANKL, MMP-1 and TIMP-1 serum levels can be potential mediators of myocardial healing after MI. However, further large studies are needed to confirm the utility of OPG and RANKL as markers of healing after ST elevation in MI.
引用
收藏
页码:510 / 516
页数:7
相关论文
共 39 条
[1]   Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction [J].
Cavusoglu, Erdal ;
Ruwende, Cyril ;
Chopra, Vincent ;
Yanamadala, Sunitha ;
Eng, Calvin ;
Clark, Luther T. ;
Pinsky, David J. ;
Marmur, Jonathan D. .
AMERICAN HEART JOURNAL, 2006, 151 (05) :1101.e1-1101.e8
[2]   Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis [J].
Collin-Osdoby, P ;
Rothe, L ;
Anderson, F ;
Nelson, M ;
Maloney, W ;
Osdoby, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (23) :20659-20672
[3]   Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction [J].
Crisafulli, A ;
Micari, A ;
Altavilla, D ;
Saporito, F ;
Sardella, A ;
Passaniti, M ;
Raffa, S ;
D'Anneo, G ;
Lucà, F ;
Mioni, C ;
Arrigo, F ;
Squadrito, F .
CLINICAL SCIENCE, 2005, 109 (04) :389-395
[5]   Pathways of matrix metalloproteinase induction in heart failure: Bioactive molecules and transcriptional regulation [J].
Deschamps, AM ;
Spinale, FG .
CARDIOVASCULAR RESEARCH, 2006, 69 (03) :666-676
[6]   Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques [J].
Dhore, CR ;
Cleutjens, JPM ;
Lutgens, E ;
Cleutjens, KBJM ;
Geusens, PPM ;
Kitslaar, PJEHM ;
Tordoir, JHM ;
Spronk, HMH ;
Vermeer, C ;
Daemen, MJAP .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (12) :1998-2003
[7]   Expression of functional major histocompatibility complex class II molecules on HMC-1 human mast cells [J].
Dimitriadou, V ;
Mécheri, S ;
Koutsilieris, M ;
Fraser, V ;
Al-Daccak, R ;
Mourad, W .
JOURNAL OF LEUKOCYTE BIOLOGY, 1998, 64 (06) :791-799
[8]  
Halapas A, 2003, IN VIVO, V17, P425
[9]  
Halapas A, 2005, THERAPY, V2, P415
[10]  
HALAPAS A, 2007, EXP PHYSIOL, V2, P237